Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates

Area of Science:

• Pharmacology
• Urology
• Molecular Biology

Background:

• Overexpression of nerve growth factor (NGF) is implicated in the development of interstitial cystitis (IC).
• Targeting NGF offers a potential therapeutic strategy for bladder disorders.

Purpose of the Study:

• To investigate intravesical instillation of antisense peptide nucleic acid (PNA) conjugates for localized reduction of NGF in the urinary bladder.
• To evaluate the efficacy of TAT-PNA conjugates in an acute cystitis rat model.

Main Methods:

• A minimum free energy algorithm was used to design antisense oligonucleotides targeting rat betaNGF mRNA.
• In vitro studies involved cotransfecting HEK293 cells with NGF cDNA to assess antisense oligo efficacy.
• An acute cystitis model in rats was induced by cyclophosphamide, followed by intravesical instillation of TAT-PNA conjugates or a scrambled control.
• Bladder function was assessed using cystometrograms, and NGF expression was measured via immunoreactivity.

Main Results:

• Intravesical instillation of TAT-PNA conjugates significantly decreased bladder contraction frequency in rats with induced cystitis compared to controls.
• NGF immunoreactivity was notably reduced in the urothelium of bladders treated with the antisense TAT-PNA conjugates.
• The study demonstrated successful delivery and localized action of the therapeutic agent within the bladder.

Conclusions:

• Intravesical administration of TAT-PNA conjugates is a feasible approach for targeted NGF reduction in the urinary bladder.
• This strategy holds promise as a novel intravesical antisense therapy for NGF-mediated bladder pathologies, including interstitial cystitis.